Abstract
Despite the approval of PD-(L)1 inhibitors for the first-line treatment of all metastatic, driver-negative, non-small cell lung cancer patients (mNSCLC) in the United States since 2018, there still is a lack discerning biomarkers to predict which patients will derive significant benefit. Tumor expression of programmed-death ligand 1 (PD-L1), measured as the tumor proportion score (TPS), is a standard biomarker approved for the selection of initial therapy. Tumor mutational burden (TMB), a promising biomarker, thought to represent the tumors’ ability to engage the host’s immune system, has demonstrated clinical utility primarily in the context of immunotherapy monotherapy. PROphetNSCLC, a test developed through proteomic analysis and machine learning, provides a novel approach by capturing biological processes from both tumor and host. In a previously published study, PROphetNSCLC, was validated to correlate with the probability of clinical benefit, independent of but also complementary to PD-L1 expression levels predicting specific treatment-related survival outcomes. Utilizing available tumor TMB measurements from this investigation, we sought to assess the correlation between the PROphetNSCLC clinical benefit probability score and TMB measurement. PROphetNSCLC demonstrated a correlation with various outcomes from PD-(L)1 inhibitor treatment independent of TMB status, whereas TMB did not exhibit an association with outcomes. This finding emphasizes the significance in of novel systemic biomarkers in refining personalized treatment strategies for mNSCLC.
Competing Interest Statement
YB,BY,IS,YE, are employees of OncoHost. DRG, KM and AD are consultants for OncoHost. IP, ML, HN, AZ, MG, RK, MM, ALB, RL, YL have no competing interest.
Clinical Trial
NCT04056247
Funding Statement
This study was funded by OncoHost, Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ClinicalTrials.gov identifier: NCT04056247) obtained approval from the institutional review board or ethics committee of all clinical sites participating in the study. Sites are listed in Data Supplement of the Original study, Table S1. (https://ascopubs.org/doi/10.1200/PO.23.00555)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos